Haemonetics to Acquire Sanquin Plasma Services for $120M
Ticker: HAE · Form: 8-K · Filed: May 21, 2024 · CIK: 313143
| Field | Detail |
|---|---|
| Company | Haemonetics Corp (HAE) |
| Form Type | 8-K |
| Filed Date | May 21, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $525 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, plasma, europe
TL;DR
Haemonetics buying Sanquin Plasma for $120M to boost European plasma collection.
AI Summary
Haemonetics Corporation announced on May 21, 2024, that it has entered into a definitive agreement to acquire Sanquin Plasma Services BV for approximately $120 million. This acquisition is expected to expand Haemonetics' plasma collection capabilities in Europe and is anticipated to close in the second half of fiscal year 2025.
Why It Matters
This acquisition signifies Haemonetics' strategic move to bolster its plasma collection infrastructure in Europe, potentially impacting its market share and supply chain for plasma-derived therapies.
Risk Assessment
Risk Level: medium — The acquisition carries integration risks and depends on regulatory approvals and market conditions for plasma-derived therapies.
Key Numbers
- $120 million — Acquisition Price (Cost to acquire Sanquin Plasma Services BV)
Key Players & Entities
- Haemonetics Corporation (company) — Acquiring company
- Sanquin Plasma Services BV (company) — Acquired company
- $120 million (dollar_amount) — Acquisition price
- May 21, 2024 (date) — Announcement date
- second half of fiscal year 2025 (date) — Expected closing period
FAQ
What is the primary strategic rationale behind Haemonetics' acquisition of Sanquin Plasma Services BV?
The acquisition is intended to expand Haemonetics' plasma collection capabilities in Europe.
What is the total purchase price for Sanquin Plasma Services BV?
The definitive agreement is for approximately $120 million.
When is the acquisition of Sanquin Plasma Services BV expected to close?
The transaction is anticipated to close in the second half of fiscal year 2025.
Which geographic region will benefit most from this acquisition?
The acquisition is expected to expand Haemonetics' plasma collection capabilities in Europe.
What is the name of the company Haemonetics Corporation is acquiring?
Haemonetics Corporation is acquiring Sanquin Plasma Services BV.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2024-05-21 16:06:07
Key Financial Figures
- $525 million — lease announcing its intention to offer $525 million aggregate principal amount of convertib
Filing Documents
- tm2415037d1_8k.htm (8-K) — 25KB
- tm2415037d1_ex99-1.htm (EX-99.1) — 13KB
- tm2415037d1_ex99-1img002.jpg (GRAPHIC) — 18KB
- 0001104659-24-063835.txt ( ) — 234KB
- hae-20240521.xsd (EX-101.SCH) — 3KB
- hae-20240521_lab.xml (EX-101.LAB) — 33KB
- hae-20240521_pre.xml (EX-101.PRE) — 22KB
- tm2415037d1_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On May 21, 2024, Haemonetics Corporation issued a press release announcing its intention to offer $525 million aggregate principal amount of convertible senior notes due 2029 in a private offering pursuant to Rule 144A under the Securities Act of 1933, as amended. A copy of the press release is furnished as Exhibit 99.1 and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release of Haemonetics Corporation dated May 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HAEMONETICS CORPORATION Date: May 21, 2024 By: /s/ James C. D'Arecca Name: James C. D'Arecca Title: Chief Financial Officer